UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-42152 EUREKA ACQUISITION CORP (Exact name of registrant as specified in its charter) | --- | --- | |-----------------------------------------|-------| | ...

8 No PRC legal counsel has been retained by the Company. The above discussion is based on our management's understanding of the current PRC laws, rules, regulations and local market practices and we cannot assure you that our management's understanding is correct. If we engage in our business combination process with a China-based target, we expect to retain legal experts in the PRC and the U.S. that are experienced with structuring offshore transactions with U.S. public companies. Additionally, we expect t ...

Delaware law and provisions in the Charter and the Bylaws could make a takeover proposal more dif icult. ● provide for a dual class common stock structure, which provides the holders of Class B Common Stock, most of whom are our management, with the ability to control the outcome of matters requiring stockholder approval, even if they collectively own significantly less than a majority of the shares of Mobix Labs' outstanding Class A Common Stock and Class B Common Stock; ● provide for a classified board of ...

We expect that carriers will need to deploy dense networks of mmWave 5G small cells and repeaters in dense urban applications in order to maintain coverage and quality of service. In rural applications, the emphasis is on coverage and efficiency of the infrastructure in energy constrained deployments. We believe these factors present significant opportunities for us. Each small cell and/or repeater will require multiple chips to meet the necessary output power and coverage requirements. Rural cells will req ...

Stock and Shareholders - The company has 48 stockholders of record and 84,815,517 shares of common stock issued and outstanding as of December 23, 2024[304] - The company issued 2,455,646 shares of common stock to Lincoln Park under the 2023 Purchase Agreement during the year ended September 30, 2024[312] - The company issued 2,450,000 purchase shares and 273,360 shares pursuant to stock option exercises in 2024[42] Dividends and Retained Earnings - The company has not paid any cash dividends and intends to retain earnings for business development[304] Research and Development - Research and development expenses for 2024 totaled $41.8 million, with $21.97 million allocated to external service providers[309] - Research and development costs are expensed as incurred, including preclinical studies, clinical trials, manufacturing costs, employee salaries, and share-based compensation[49] - Nonrefundable advance payments for future R&D activities are deferred and amortized over the period goods are delivered or services are performed[49] - The company estimates costs related to external CROs and clinical site costs, accruing expenses based on work performed and stage of completion[49] - Accrued CRO costs are subject to revisions as trials progress, with revisions charged to expense in the period they become known[49] - Clinical site cost payments depend on factors like patient recruitment, trial completion, or achievement of specific events[49] - The company expenses the acquisition of patents and trademarks due to uncertainties in commercialization[49] Cash Flow and Financial Position - The company's cash and cash equivalents decreased to $132.2 million as of September 30, 2024, from $151.0 million in 2023[311] - Cash flow used in operating activities increased by $3.0 million in fiscal 2024, primarily due to higher net cash expenses[311] - The company entered into a $150 million purchase agreement with Lincoln Park Capital Fund, LLC, with $110.8 million remaining available as of September 30, 2024[311][312] Agreements and Terminations - The company terminated the 2020 Sales Agreement on July 24, 2024[316] - The company is party to an exclusive license agreement with Life Science Research Israel Ltd. for the ANAVEX3-71 product candidate[317] Intellectual Property Risks - The company may face disputes over intellectual property rights, which could impact its ability to develop and commercialize products[317] Tax and Valuation Allowance - The company reduced federal NOLs by $12.1 million and R&D tax credit carryforwards by $0.8 million due to a Section 382 study[33] - A change in ownership in 2015 resulted in $25.8 million of federal NOLs being subject to an annual limitation[33] - The company recorded a reduction of $2.5 million in NOLs and $0.8 million in R&D credits, with a corresponding $3.3 million reduction in valuation allowance[33] - As of September 30, 2024, the company did not provide foreign withholding taxes on undistributed earnings of foreign subsidiaries[33] Share-Based Compensation and Financial Results - Share-based compensation for 2024 amounted to $9,438[42] - The company reported a net loss of $43,002 for the year ended September 30, 2024[42] - Total additional paid-in capital as of September 30, 2024, was $456,249[42] - Accumulated deficit as of September 30, 2024, was $336,071[42] Internal Controls and Financial Reporting - The company’s internal controls over financial reporting were effective as of September 30, 2024[45] Board of Directors and Governance - The Board of Directors is composed of a majority of independent directors, with Dr. Jiong Ma serving as the independent Board Chair[47] - The Board oversees risk management, including economic, operational, financial, competitive, legal, regulatory, cybersecurity, compliance, and reputational risks[47] - The Audit, Compensation, and Nominating and Corporate Governance Committees oversee specific areas of responsibility[47] - Christopher Missling, PhD, serves as Director, President, CEO, and Secretary, appointed on July 5, 2013[48]

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 1141 Cummings Road Santa Paula, CA 93060 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (805) 525-5541 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $0.01 LMNR The NASDAQ Stock Market LLC (NASDAQ Global Select Market) Securities registered ...

| --- | |------------------------------------| | Nevada | | (State or Other Jurisdiction | | --- | --- | --- | |----------------------------------------|---------------------|-----------------------------------------------------| | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common Stock, par value $0.001 | UPXI | NASDAQ | Emerging growth company ☒ Item 2.02 Results of Operations and Financial Condition. Section 9 – Financial Statements and Exhibits Certain statem ...

Net Revenues Grew 6% to a Record $191.5 Million in Fiscal Year 2024 Compared to Prior Year Driven by Record $25.1 Million Avocado Sales LIMONEIRA Achieved Year-Over-Year Pricing Improvement in Fresh Lemons and Avocados for Fiscal Year 2024 Strategic Alternatives Exploration to Maximize Stockholder Value Continues to Progress Management Comments Mr. Edwards continued, "Our Harvest at Limoneira residential real estate joint venture with the Lewis Group of Companies ("Lewis") continues to perform very well and ...

Exhibit 99.1 QUARTER ENDED NOVEMBER 30, 2024 AND DECLARES QUARTERLY DIVIDEND • Revenues were $99.8 million for the quarter compared to $104.6 million for the same quarter last year, a decrease of $4.8 million or -4.6%. • Earnings per diluted share for the current quarter were $0.39 compared to $0.38 for the comparative quarter last year. • Our gross profit margin for the quarter was 29.3% compared to 29.2% for the comparative quarter last year. • The Board approved a special dividend of $2.50 per share paid ...

Unbilled accounts receivable The Company has recorded $19.7 million and $16.6 million of unbilled accounts receivable on the consolidated balance sheets as of October 31, 2024 and January 31, 2024, respectively, from revenues generated by certain of its subsidiaries. The Company has fulfilled all performance obligations and has recorded revenue under the respective contracts. The deliverables under these contracts have been accepted by the customer and billings will be made once the customer takes possessio ...